Dr. Yuichi Iwaki is the Founder, President, and CEO of MediciNova, a publicly traded, clinical-stage biopharmaceutical company developing therapies for serious diseases with significant unmet medical need. A physician-scientist by training, Iwaki earned both his M.D. and Ph.D. from Sapporo Medical School before launching an academic career at UCLA and later leading the Transplant Immunology Laboratory at the University of Pittsburgh, where he contributed to clinical trials behind breakthrough transplant therapies including Cyclosporin and Prograf. That grounding in translational science shaped the company he would go on to build.
Based in La Jolla, California, MediciNova is advancing a capital-efficient, data-driven pipeline anchored by MN-166 (ibudilast), currently in late-stage development for amyotrophic lateral sclerosis (ALS), alongside MN-001 (tipelukast) for metabolic and fibrotic conditions. In this Q&A, Iwaki discusses the clinical experience that led him to found the company, how MediciNova's lean operating model and non-dilutive partnerships help advance a late-stage pipeline without heavy infrastructure, the milestones ahead as MN-166 approaches regulatory discussions with the FDA, and what he'd change about drug development timelines industry-wide.
Your Story
Q1. What was the defining moment or insight that led you to take the helm of MediciNova?
The defining insight came from a combination of clinical experience and observing gaps in drug development. During my work in transplantation and clinical trials, I saw firsthand how transformative it can be when a therapy successfully moves from the laboratory into clinical practice. At the same time, I became increasingly aware that many promising compounds were not being fully developed — often because of strategic or financial constraints rather than scientific limitations.
That realization stayed with me. I saw an opportunity to build a company that could take a more focused, disciplined approach: identifying compounds with strong scientific rationale and advancing them in areas where patients had very few options. Neurodegenerative diseases such as ALS stood out because of the profound unmet need and limited therapeutic progress. Founding MediciNova was a way to bring together my experience in science, clinical medicine, and drug development strategy to address those challenges directly.
Q2. In the simplest terms, what does MediciNova do, and why does it matter for patients?
At its core, MediciNova develops therapies for serious diseases where patients have limited or no effective treatment options. We focus on identifying compounds with well-understood biological mechanisms and applying them in ways that can meaningfully impact disease progression.
For patients — particularly those with ALS or other progressive neurological diseases — current treatment options are often limited and provide only modest benefit. Our goal is to go beyond symptom management and develop therapies that can potentially slow or alter the course of disease. If we succeed, it means giving patients more time, improved quality of life, and a sense that progress is finally being made in areas that have historically seen very little advancement.
The Science & The Strategy
Q3. What about your approach — your pipeline, your strategy — sets MediciNova apart?
What differentiates our approach is the combination of scientific discipline and strategic focus. We prioritize compounds with a strong mechanistic foundation and supporting evidence, whether from previous approvals in other indications or highly effective preclinical data, rather than pursuing highly speculative approaches. MN-166, for example, targets neuroinflammation, which is increasingly understood to play a central role across multiple neurodegenerative diseases.
We also take a data-driven approach to development. Rather than forcing a program to fit a predetermined strategy, we let clinical and scientific data guide decision-making at every stage, which helps reduce risk and ensures resources are allocated effectively. Our capital-efficient operating model is another key differentiator — it allows us to advance meaningful programs without the burden of large infrastructure, while staying flexible and focused on patient needs.
Q4. What has been your most important milestone to date, and what's next?
One of our most significant recent milestones was completing patient enrollment in our Phase 2b/3 COMBAT-ALS trial for MN-166, along with reaching target enrollment for the trial's expanded access program. Successfully recruiting for a complex trial in this space, while maintaining a strong safety profile, has been a major achievement for our clinical team and the ALS community.
Looking ahead, our next major milestone is analyzing the trial's top-line data and advancing MN-166 toward regulatory discussions with the FDA. Beyond ALS, we're also progressing our late-stage pipeline across other neurodegenerative indications. Reaching these goals would be a transformative step forward for MediciNova and for the patients who urgently need new options.
Q5. MediciNova runs a lean, capital-efficient model. How do you advance multiple late-stage programs without inflating overhead?
Our strategy centers on leverage and scientific collaboration. Rather than building costly internal infrastructure, we work closely with government agencies, academic institutions, and grant-funding bodies — including the NIH and NINDS — to support clinical initiatives like our expanded access programs and investigator-sponsored trials. This non-dilutive, partner-driven approach lets us advance high-value programs like MN-166 and MN-001 efficiently, keeping our focus sharp while directing every dollar toward patient care and data generation.
Q6. MN-166 is best known for its late-stage work in ALS, but your platform reaches further. How do you view its broader potential?
One of the most compelling aspects of our pipeline is that our lead compounds target core biological mechanisms — neuroinflammation, oxidative stress, and fibrotic pathways — shared across multiple devastating conditions. With MN-166, targeting phosphodiesterase-4 (PDE4) and macrophage migration inhibitory factor (MIF) lets us evaluate its therapeutic potential not only in ALS, but also in progressive multiple sclerosis, degenerative cervical myelopathy (DCM), and oncology applications like glioblastoma. Similarly, MN-001 (tipelukast) targets fibrotic and metabolic pathways, with applications in hypertriglyceridemia and fatty liver disease. This multi-indication capability maximizes the impact of our science and creates multiple avenues to deliver value to patients.
Leadership & Ecosystem
Q7. What has surprised you most about being a CEO in life sciences?
One of the most surprising aspects of the role is the constant need to balance long-term scientific progress with shorter-term expectations from stakeholders, including investors and partners. Scientific development requires patience — meaningful results can take years to achieve — yet there's also an expectation for regular updates and visible progress.
Managing that balance requires clear communication and disciplined decision-making. It's important to stay focused on the long-term goal of delivering effective therapies, while making sure stakeholders understand the progress being made along the way. That dual responsibility is both challenging and essential to leading a successful life sciences company.
Q8. What role does the San Diego life sciences ecosystem play in MediciNova's growth?
Being based in the San Diego area gives us access to a diverse and well-established life sciences ecosystem — leading academic institutions, experienced clinical investigators, and a strong network of biotechnology professionals — which creates opportunities for collaboration and expertise across multiple disciplines.
At the same time, Southern California offers a level of flexibility and cost efficiency compared to some of the larger biotech hubs. That aligns well with our operating model, allowing us to leverage high-quality resources while maintaining a disciplined approach to spending. The ecosystem supports both innovation and execution, which are critical to our growth.
Looking Ahead
Q9. Where do you see MediciNova in three years, and what will have to go right to get there?
In three years, we aim to have advanced MN-166 through the regulatory process and, ideally, be able to bring it to patients. Achieving this will depend on strong clinical execution, clear and compelling data, and productive engagement with regulatory agencies. Beyond ALS, we also see opportunities to expand MN-166 into additional indications where neuroinflammation plays a role, which would significantly broaden the program's impact. Ultimately, reaching these goals will require continued discipline, focus, and a commitment to following the science.
Q10. What's one thing about the life sciences industry today you'd change — and what gives you optimism despite it?
One area that could be improved is the overall efficiency of drug development. The process is often lengthy and costly, which can limit the number of therapies ultimately brought forward and delay access for patients. Finding ways to streamline development — while maintaining scientific rigor and patient safety — would have a meaningful impact on the industry.
What gives me optimism is the continued advancement of scientific understanding and the growing emphasis on more efficient development models. We're seeing increased collaboration, better use of data, and new approaches to clinical trial design — trends that have the potential to accelerate progress and bring more effective treatments to patients in a shorter period of time.
About The Big4Bio CEO Weekly Q&A
Every Monday, Big4Bio spotlights a life sciences CEO from one of our eight coverage regions — Boston, San Francisco Bay Area, San Diego, Philadelphia, New York City, the Capital Region, Los Angeles, and Seattle. Each feature is promoted across all eight Big4Bio daily newsletters, reaching 30,000+ life sciences professionals. CEO participation is complimentary and editorial — every CEO approves the final Q&A before publication.
Are you a life sciences CEO or do you represent one? Contact Big4Bio editor Marie Daghlian at marie@big4bio.com to be considered for an upcoming feature.